Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment | Zendy

Rebecca Edwards | Zendy; Christine Andan | Zendy; Rajesh V. Lalla | Zendy; Mario E. Lacouture | Zendy; Dennis O’Brien | Zendy; Lecia V. Sequist | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment

Author(s) -

Rebecca Edwards,

Christine Andan,

Rajesh V. Lalla,

Mario E. Lacouture,

Dennis O’Brien,

Lecia V. Sequist

Publication year - 2018

Publication title -

clinical journal of oncology nursing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.375

H-Index - 43

eISSN - 1538-067X

pISSN - 1092-1095

DOI - 10.1188/18.cjon.542-548

Subject(s) - afatinib , medicine , tolerability , adverse effect , oncology , lung cancer , epidermal growth factor receptor , clinical trial , intensive care medicine , cancer , erlotinib

Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research